Use of Mendelian randomization to assess the causal status of modifiable exposures for rheumatic diseases
Open Access
- 30 June 2024
- journal article
- research article
- Published by Elsevier in Best Practice & Research Clinical Rheumatology
- Vol. 38 (4) , 101967
Abstract
No abstract availableKeywords
This publication has 62 references indexed in Scilit:
- Methotrexate and the Risk of Dementia: A Two-Sample Mendelian Randomization StudyNeurology and Therapy, 2024
- Metformin treatment reduces the incidence of osteoporosis: a two-sample Mendelian randomized studyOsteoporosis International, 2024
- Statin Use, Lipids, and 3-Hydroxy-3-Methyl-Glutaryl Coenzyme A Reductase Inhibition on Risk of Idiopathic Pulmonary FibrosisClinical Therapeutics, 2023
- Challenges in undertaking nonlinear Mendelian randomizationObesity, 2023
- Effects of blood pressure and antihypertensive drugs on osteoarthritis: a mendelian randomized studyAging Clinical and Experimental Research, 2023
- Lowering of Circulating Sclerostin May Increase Risk of Atherosclerosis and Its Risk Factors: Evidence From a Genome‐Wide Association Meta‐Analysis Followed by Mendelian RandomizationArthritis & Rheumatology, 2023
- T Helper 2 IL-4/IL-13 Dual Blockade with Dupilumab Is Linked to Some Emergent T Helper 17‒Type Diseases, Including Seronegative Arthritis and Enthesitis/Enthesopathy, but Not to Humoral Autoimmune DiseasesJournal of Investigative Dermatology, 2022
- Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian RandomizationJAMA, 2021
- Mendelian randomization study shows no causal relationship between circulating urate levels and Parkinson's diseaseAnnals of Neurology, 2018
- Statins and Risk of Rheumatoid Arthritis: A Nested Case–Control StudyArthritis & Rheumatology, 2016